Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors

Drug Metabolism and Disposition

Volumn 35, Issue 3, 2007, Pages 493-500

  Ekins, Sean ^a,b   Mankowski, Dayna C ^a,c   Hoover, Dennis J ^a   Lawton, Michael P ^a   Treadway, Judith L ^a   Harwood Jr , H James ^a  

^a PFIZER INC   (United States)

^b ACT LLC   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ARACHIDONIC ACID; BENZIMIDAZOLE; BIFONAZOLE; CHLORPROPAMIDE; CLOTRIMAZOLE; CP 320626; CYTOCHROME P450 51 INHIBITOR; CYTOCHROME P450 INHIBITOR; ECONAZOLE; ERYTHROMYCIN; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MEVINOLIN; MICONAZOLE; PREGNENOLONE; PROGESTERONE; PROPAFENONE; RIFAMPICIN; SULFAPHENAZOLE; SULFINPYRAZONE; TERCONAZOLE; TESTOSTERONE; THIAMAZOLE; TOLBUTAMIDE; TOLNAFTATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; COMPUTER PROGRAM; DEMETHYLATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; IC 50; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

AMIDES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; INDOLES; MODELS, MOLECULAR; OXIDOREDUCTASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847411922     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013888     Document Type: Article

References (62)

1. Aoyama Y, Noshiro M, Gotoh O, Imaoka S, Funae Y, Kurosawa N, Horiuchi T, and Yoshida Y (1996) Sterol 14-demethylase P450 (P45014DM) is one of the most ancient and conserved P450 species. J Biochem (Tokyo) 119:926-933.
2. Aoyama Y, Yoshida Y, Hata S, Nishino T, and Katsuki H (1983) Buthiobate: a potent inhibitor for yeast cytochrome P-450 catalyzing 14α-demethylation of lanosterol. Biochem Biophys Res Commun 115:642-647.
3. Aoyama Y, Yoshida Y, Sonoda Y, and Sato Y (1987) 7-Oxo-24,25- dihydrolanosterol: a novel lanosterol 14α-demethylase (P-450(14DM)) inhibitor which blocks electron transfer to the oxyferro intermediate. Biochim Biophys Acta 922:270-277.
4. Boscott PE and Grant GH (1994) Modeling cytochrome P450 14α demethylase (Candida albicans) from P450cam. J Mol Graph 12:185-192, 195.
5. Chan JR, Phillips LJ 2nd, and Glaser M (1998) Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc Natl Acad Sci USA 95:10459-10464.
6. de Groot MJ and Ekins S (2002) Pharmacophore modeling of cytochromes P450. Adv Drug Del Rev 54:367-383.
7. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT, and Murray GI (2005) Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 11:7369-7375.
8. Ekins S, Berbaum J, and Harrison RK (2003) Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 31:1077-1080.
9. Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, VandenBranden M, Wrighton SA, and Wikel JH (1999) Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharmacol Exp Ther 288:21-29.
10. Ekins S, de Groot M, and Jones JP (2001) Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 29:936-944.
11. Ekins S and Swaan PW (2004) Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX. Rev Comp Chem 20:333-415.
12. Frye LL, Cusack KP, and Leonard DA (1993) 32-Methyl-32-oxylanosterols - dual-action inhibitors of cholesterol biosynthesis. J Med Chem 36:410-416.
13. Frye LL, Cusack KP, Leonard DA, and Anderson JA (1994) Oxolanosterol oximes - dual-action inhibitors of cholesterol biosynthesis. J Lipid Res 35:1333-1344.
14. Fujita T (1997) Recent success stories leading to commercializable bioactive compounds with the aid of traditional QSAR procedures. Quant Struct-Act Relat 16:107-112.
15. Gebhardt R, Beck H, and Wagner KG (1994) Inhibition of cholesterol biosynthesis by allicin and ajoene in rat hepatocytes and HepG2 cells. Biochim Biophys 1994:57-62.
16. Hahn M and Rogers D (1995) Receptor surface models 2: application to quantitative structure-activity relationships studies. J Med Chem 38:2091-2102.
17. Hartman PG and Sanglard D (1997) Inhibitors of ergosterol biosynthesis as antifungal agents: recent success stories leading to commercializable bioactive compounds with the aid of traditional QSAR procedures. Curr Pharm Des 3:177-208.
18. Harwood H and Hamanaka E (1998) Modulators of dyslipidemia. Emerging Drugs 3:147-172.
19. Harwood HJ Jr, Petras SF, Hoover DJ, Mankowski DC, Soliman VF, Sugarman ED, Hulin B, Kwon Y, Gibbs EM, Mayne JT, et al. (2005) Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase. J Lipid Res 46:547-563.
20. Hiroi T, Imaoa S, and Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838-843.
21. Holtje HD and Fattorusso C (1998) Construction of a model of the Candida albicans lanosterol 14-α-demethylase active site using the homology modelling technique. Pharm Acta Helv 72:271-277.
22. Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, Martin WH, Armento SJ, Stock IA, McPherson RK, Genereux PE, Gibbs EM, and Treadway JL (1998) Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J Med Chem 41:2934-2938.
23. Ishida N, Aoyama Y, Hatanaka R, Oyama Y, Imajo S, Ishiguro M, Oshima T, Nakazato H, Noguchi T, Maitra US, et al. (1988) A single amino acid substitution converts cytochrome P450(14DM) to an inactive form, cytochrome P450(SG1): complete primary structures deduced from cloned DNAs. Biochem Biophys Res Commun 155:317-323.
24. Ji H, Zhang W, Zhou Y, Zhang M, Zhu J, Song Y, Lu J, and Zhu J (2000) A three dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 43:2493-2505.
25. Jones JP, He M, Trager WF, and Rettie AE (1996) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 24:1-6.
26. Kelly SL, Lamb DC, Baldwin BC, Corran AJ, and Kelly DE (1997) Characterization of Saccharomyces cerevisiae CTP61, sterol -Δ22-desaturase, and inhibition by azole antifungal agents. J Biol Chem 272:9986-9988.
27. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, and Murray GI (2005) Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 11:3758-3765.
28. Lamb DC, Kelly DE, and Kelly SL (1998) Molecular diversity of sterol 14-α-demethylase substrates in plants, fungi and humans. FEBS Lett 425:263-265.
29. Lewis DFV, Wiseman A, and Tarbit MH (1999) Molecular modelling of lanosterol 14α-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. J Enzyme Inhib 14:175-192.
30. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, and Treadway JL (1998) Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci USA 95:1776-1781.
31. Matsuura K, Yoshioka S, Tosha T, Hori H, Ishimori K, Kitagawa T, Morishima I, Kagawa N, and Waterman MR (2005) Structural diversities of active site in clinical azole-bound forms between sterol 14α-demethylases (CYP51s) from human and Mycobacterium tuberculosis. J Biol Chem 280:9088-9096.
32. Miettinen TA (1988) Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29:43-51.
33. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
34. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
35. Podust LM, Poulos TL, and Waterman MR (2001) Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 98:3068-3073.
36. Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR, Mathiowetz AM, McPherson RK, Olson TV, Treadway JL, et al. (2000) Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem Biol 7:677-682.
37. Rozman D, Stromstedt M, Tsui LC, Scherer SW, and Waterman MR (1996) Structure and mapping of the human lanosterol 14α-demethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes. Genomics 38:371-381.
38. Rupp B, Raub S, Marian C, and Holtje HD (2005) Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole. J Comput Aided Mol Des 19:149-163.
39. Sonoda Y, Endo M, Ishida K, Sato Y, Fukusen N, and Fukuhara M (1993) Purification of a human cytochrome P-450 isozyme catalyzing lanosterol 14α-demethylation. Biochim Biophys Acta 1170:92-97.
40. Stehmann C and de Waard M (1995) Relationship between chemical structure and biological activity of triazole fungicides against Botrytis cinerea. Pestic Sci 44:183-195.
41. Strolin Benedetti M and Bani M (1999) Metabolism-based drug interactions involving oral azole antifungals in humans. Drug Metab Rev 31:665-671.
42. Stromstedt M, Rozman D, and Waterman MR (1996) The ubiquitously expressed human CYP51 encodes lanosterol 14-α-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Arch Biochem Biophys 329:73-81.
43. Stromstedt M, Waterman MR, Haugen TB, Tasken K, Parvinen M, and Rozman D (1998) Elevated expression of lanosterol 14α-demethylase (CYP51) and the synthesis of oocyte meiosis-activating sterols in postmeiotic germ cells of male rats. Endocrinology 139:2314-2321.
44. Sundin M, Warner M, Haaparanta T, and Gustafsson JA (1987) Isolation and catalytic activity of cytochrome P-450 from ventral prostate of control rats. J Biol Chem 262:12293-12297.
45. Tafi A, Anastassopoulou J, Theophanides T, Botta M, Corelli F, Massa S, Artico M, Costi R, Di Santo R, and Ragno R (1996) Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. J Med Chem 39:1227-1235.
46. Talele TT, Hariprasad V, and Kulkarni VM (1997) Docking analysis of a series of cytochrome P-450(14)α DM inhibiting azole antifungals. Drug Des Discov 15:181-190.
47. Treadway JL, Mendys P, and Hoover DJ (2001) Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 10:439-454.
48. Trzaskos J, Kawata S, and Gaylor JL (1986) Microsomal enzymes of cholesterol biosynthesis: purification of lanosterol 14α-methyl demethylase cytochrome P-450 from hepatic microsomes. J Biol Chem 261:14651-14657.
49. Trzaskos JM, Ko SS, Magolda RL, Favata MF, Fischer RT, Stam SH, Johnson PR, and Gaylor JL (1995) Substrate-based inhibitors of lanosterol 14α-methyl demethylase: I. Assessment of inhibitor structure-activity relationship and cholesterol biosynthesis inhibition properties. Biochemistry 34:9670-9676.
50. Trzaskos JM, Magolda RL, Favata MF, Fischer RT, Johnson PR, Chen HW, Ko SS, Leonard DA, and Gaylor JL (1993) Modulation of 3-hydroxy-3-methylglutaryl- CoA reductase by 15-α-fluorolanost-7-en-3-β-Ol: a mechanism-based inhibitor of cholesterol biosynthesis. J Biol Chem 268:22591- 22599.
51. Tsukuda T, Shiratori Y, Watanabe M, Ontsuka H, Hattori K, Shirai M, and Shimma N (1998) Modeling, synthesis and biological activity of novel antifungal agents (1). Bioorg Med Chem Lett 8:1819-1824.
52. Tuck EF, Robinson CH, and Silverton JV (1991) Assessment of the active-site requirements of lanosterol 14α-demethylase: evaluation of novel substrate analogues as competitive inhibitors. J Org Chem 56:1260-1266.
53. SG1). J Biol Chem 267:13175-13179.
54. Vanden Bossche H and Koymans L (1998) Cytochromes P450 in fungi. Mycoses 41:32-38.
55. Vanden Bossche H, Koymans L, and Moereels H (1995) P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 67:79-100.
56. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Verhoeven H, Coene M-C, Lauwers W, and Janssen PAJ (1987) Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pestic Sci 21:289-306.
57. Waterman MR and Lepesheva GI (2005) Sterol 14α-demethylase, an abundant and essential mixed-function oxidase. Biochem Biophys Res Commun 338:418-422.
58. Wrighton SA, Ring BJ, and VandenBranden M (1995) The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 23:199-208.
59. Yoshida Y and Aoyama Y (1985) Effects of buthiobate, a fungicide, on cytochrome P-450 of rat liver microsomes. J Pharmacobiodyn 8:432-439.
60. Yoshida Y and Aoyama Y (1987) Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol 36: 229-235.
61. Yoshida Y, Noshiro M, Aoyama Y, Kawamoto T, Horiuchi T, and Gotoh O (1997) Structural and evolutionary studies on sterol 14-demethylase P450 (CYP51), the most conserved P450 monooxygenase: II. Evolutionary analysis of protein and gene structures. J Biochem (Tokyo) 122:1122-1128.
62. Yu LJ, Chen Y, Treadway JL, McPherson RK, McCoid SC, Gibbs EM, and Hoover DJ (2006) Establishment of correlation between in vitro enzyme binding potency and in vivo pharmacological activity: application to liver glycogen phosphorylase a inhibitors. J Pharmacol Exp Ther 317:1230-1237.